Echtzeitdetektion von Punktmutationen mit DNA-Chips am Beispiel des SULT1A1*213-SNP

Der Identifizierung von Punktmutationen im menschlichen Genom kommt eine hohe Bedeutung zu. Die Entdeckung einer Vielzahl von SNPs ('single nucleotide polymorphisms'), also Mutationen einzelner Basen, die definitionsgemäß bei mehr als 1% der Bevölkerung auftreten, und die Erkenntnis, dass SNPs die Nebenwirkungen von Medikamenten determinieren können, führte zu der Vision einer 'personalisierten Medizin': Der Patient erhält nach einer Genotypisierung das für ihn verträglichste Medikament verschrieben. Notwendige Bedingung für das neue Paradigma ist eine schnelle und hochdurchsatzfähige DNA-Analytik. Da bis zu 3 Millionen von SNPs beim Menschen vermutet werden (www.snp.cshl.org), ist das etablierte Verfahren mittels PCR-Amplifikation, Restriktionsenzymverdau und Elektrophorese nicht praktikabel. Neben den zum Massenscreening geeigneten, spezialisierten MALDI- (z.B. Sequenom ®) und Primer-Extension-Verfahren (z.B. Orchid Biocomputer ®) wird insbesondere die DNA-Chip-Technologie als vielversprechende Methode für mittlere bis hohe Durchsätze und Vor-Ort-Anwendungen angesehen. Der Einsatz dieses Verfahrens zum SNP-Screening wird am Beispiel des SULT1A1*213-SNPs demonstriert. Das SULT1A1-Gen beim Menschen kodiert für eine cytosolische, thermostabile Phenol-Sulfotransferase (P-PST, EC 2.8.2.1), die in der Leber durch Sulfonierung von phenolischen Substraten Biosynthese und Entgiftungsfunktionen ausübt. Bisher wurden drei Punktmutationen in diesem Gen entdeckt (Raftogianis 1997). Die Variation *213Arginin nach *213Histidin, die bei ca. 37% der (kaukasischen) Bevölkerung auftritt, führt zu einem deutlich verschiedenen Phänotyp (geringere Aktivität, geringere Thermostabilität, Engelke 2000) und wird mit Übergewicht in Zusammenhang gebracht

Messgerät zur Lumineszenzmessung

The invention relates to a measuring device for luminescence measurement comprising a sample carrier (8) for receiving a luminescent sample (9), a first lens array (13) having numerous lenses (14) arranged in a grid-shaped fashion and serving for focusing luminescent radiation emerging from the luminescent sample (9), and comprising a light sensor (16) for detecting the luminescent radiation emitted by the luminescent sample (9), wherein the light sensor (16) is arranged downstream of the first lens array (13) in the beam path of the luminescent radiation. It is proposed that the first lens array (13) is a first microlens array (13) having numerous microlenses (14), wherein a first perforated mask (11) having numerous holes (12) is arranged in the beam path of the luminescent radiation between the sample carrier (8) and the first microlens array (13), wherein the individual microlenses (14) and the holes (12) are assigned to one another and have corresponding axes. The sample carrier (8) can have a substantially planar waveguide (8), wherein the excitation radiation from an illumination unit (1) is coupled into a waveguide edge (10) of the waveguide (8)

Integrated planar optical waveguide interferometer biosensors: A comparative review

Integrated planar optical waveguide interferometer biosensors are advantageous combinations of evanescent field sensing and optical phase difference measurement methods. By probing the near surface region of a sensor area with the evanescent field, any change of the refractive index of the probed volume induces a phase shift of the guided mode compared to a reference field typically of a mode propagating through the reference arm of the same waveguide structure. The interfering fields of these modes produce an interference signal detected at the sensor׳s output, whose alteration is proportional to the refractive index change. This signal can be recorded, processed and related to e.g. the concentration of an analyte in the solution of interest. Although this sensing principle is relatively simple, studies about integrated planar optical waveguide interferometer biosensors can mostly be found in the literature covering the past twenty years. During these two decades, several members of this sensor family have been introduced, which have remarkably advantageous properties. These entail label-free and non-destructive detection, outstandingly good sensitivity and detection limit, cost-effective and simple production, ability of multiplexing and miniaturization. Furthermore, these properties lead to low reagent consumption, short analysis time and open prospects for point-of-care applications. The present review collects the most relevant developments of the past twenty years categorizing them into two main groups, such as common- and double path waveguide interferometers. In addition, it tries to maintain the historical order as it is possible and it compares the diverse sensor designs in order to reveal not only the development of this field in time, but to contrast the advantages and disadvantages of the different approaches and sensor families, as well

Integrated planar optical waveguide interferometer biosensors : a comparative review

Integrated planar optical waveguide interferometer biosensors are advantageous combinations of evanescent field sensing and optical phase difference measurement methods. By probing the near surface region of a sensor area with the evanescent field, any change of the refractive index of the probed volume induces a phase shift of the guided mode compared to a reference field typically of a mode propagating through the reference arm of the same waveguide structure. The interfering fields of these modes produce an interference signal detected at the sensor׳s output, whose alteration is proportional to the refractive index change. This signal can be recorded, processed and related to e.g. the concentration of an analyte in the solution of interest. Although this sensing principle is relatively simple, studies about integrated planar optical waveguide interferometer biosensors can mostly be found in the literature covering the past twenty years. During these two decades, several members of this sensor family have been introduced, which have remarkably advantageous properties. These entail label-free and non-destructive detection, outstandingly good sensitivity and detection limit, cost-effective and simple production, ability of multiplexing and miniaturization. Furthermore, these properties lead to low reagent consumption, short analysis time and open prospects for point-of-care applications. The present review collects the most relevant developments of the past twenty years categorizing them into two main groups, such as common- and double-path waveguide interferometers. In addition, it tries to maintain the historical order as it is possible and it compares the diverse sensor designs in order to reveal not only the development of this field in time, but to contrast the advantages and disadvantages of the different approaches and sensor families, as well

Detection of Antibodies against Endemic and SARS-CoV-2 Coronaviruses with Short Peptide Epitopes

(1) Background: Coronavirus proteins are quite conserved amongst endemic strains (eCoV) and SARS-CoV-2. We aimed to evaluate whether peptide epitopes might serve as useful diagnostic biomarkers to stratify previous infections and COVID-19. (2) Methods: Peptide epitopes were identified at an amino acid resolution that applied a novel statistical approach to generate data sets of potential antibody binding peptides. (3) Results: Data sets from more than 120 COVID-19 or eCoV-infected patients, as well as vaccinated persons, have been used to generate data sets that have been used to search in silico for potential epitopes in proteins of SARS-CoV-2 and eCoV. Peptide epitopes were validated with >300 serum samples in synthetic peptide micro arrays and epitopes specific for different viruses, in addition to the identified cross reactive epitopes. (4) Conclusions: Most patients develop antibodies against non-structural proteins, which are useful general markers for recent infections. However, there are differences in the epitope patterns of COVID-19, and eCoV, and the S-protein vaccine, which can only be explained by a high degree of cross-reactivity between the viruses, a pre-existing immune response against some epitopes, and even an alternate processing of the vaccine proteins

Anti-hemagglutinin antibody derived lead peptides for inhibitors of influenza virus binding

Antibodies against spike proteins of influenza are used as a tool for characterization of viruses and therapeutic approaches. However, development, production and quality control of antibodies is expensive and time consuming. To circumvent these difficulties, three peptides were derived from complementarity determining regions of an antibody heavy chain against influenza A spike glycoprotein. Their binding properties were studied experimentally, and by molecular dynamics simulations. Two peptide candidates showed binding to influenza A/Aichi/2/68 H3N2. One of them, termed PeB, with the highest affinity prevented binding to and infection of target cells in the micromolar region without any cytotoxic effect. PeB matches best the conserved receptor binding site of hemagglutinin. PeB bound also to other medical relevant influenza strains, such as human-pathogenic A/California/7/2009 H1N1, and avian-pathogenic A/Mute Swan/Rostock/R901/2006 H7N1. Strategies to improve the affinity and to adapt specificity are discussed and exemplified by a double amino acid substituted peptide, obtained by substitutional analysis. The peptides and their derivatives are of great potential for drug development as well as biosensing

Enhancement of peptide binding affinity to HA by site-directed substitution.

<p>A) Inhibition of Aichi H3N2 binding to immobilized fetuin by PeB-Lys and PeB^GF-Lys as determined via SPR (n = 2). Error bars indicate the SEM. Dashed lines represent a four parameter logistic fit. B) Microarray based substitutional analysis of PeB using fluorescently labeled Aichi H3N2 viruses as analytes (for further virus strains see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0159074#pone.0159074.s007" target="_blank">S7 Fig</a>). Amino acids in the first row represent that of PeB, while amino acids in the first column show the substitution. The values represent the contrast relative to fetuin as positive control (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0159074#sec002" target="_blank">Material and Methods</a>). C) Binding of different viruses to selected immobilized single and double amino acid substituted variants of peptide PeB-Lys. The binding response from SPR measurements is shown (as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0159074#pone.0159074.g003" target="_blank">Fig 3</a>).</p